SCHEMBL6999527

SCHEMBL6999527

CC(=O)Oc1ccc2c(CN3C(=O)c4ccccc4C3=O)cc(=O)oc2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
KDM4E B2RXH2 7/20 0.48
ALDH1A1 P00352 6/20 0.48
GAA P10253 4/20 0.48
HPGD P15428 7/20 0.48
KMT2A Q03164 6/20 0.48
GLA P06280 2/20 0.48
HSD17B10 Q99714 2/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 1/20 0.48
GBA1 P04062 1/20 0.46
PSMD14 O00487 1/20 0.45
MMP2 P08253 1/20 0.45
BLM P54132 1/20 0.45
MEN1 O00255 3/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HSP90AA1 P07900 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MAOA P21397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6993082 0.85 KDM4E (0.57) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL6991273 0.83 MAPT (0.59) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL7002316 0.83 KDM4E (0.58) KDM4EALDH1A1GAAHPGDKMT2A
SCHEMBL6996195 0.80 ALDH1A1 (0.60) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL6999092 0.79 PON1 (0.64) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL6993105 0.76 KDM4E (0.73) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL18073970 0.75 KDM4E (0.55) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL8361989 0.75 KDM4E (0.56) MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL6993944 0.72 ALDH1A1 (0.62) MAPTKDM4EALDH1A1HPGDKMT2A
SCHEMBL7000666 0.71 ALDH1A1 (0.63) MAPTKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032265-B1 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORP (US) 2003-10-29 EP disclosed
US-20030082510-A1 Psoralens for pathogen inactivation CERUS CORPORATION (US) 2003-05-01 US disclosed
US-6455286-B1 MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN CERUS CORPORATION 2002-09-24 US disclosed
EP-1032265-A4 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORP (US) 2001-05-30 EP disclosed
US-6133460-A HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID CERUS CORPORATION (US) 2000-10-17 US disclosed
EP-1032265-A1 NEW PSORALENS FOR PATHOGEN INACTIVATION Cerus Corporation (US) 2000-09-06 EP disclosed
WO-1999026476-A1 NEW PSORALENS FOR PATHOGEN INACTIVATION CERUS CORPORATION (US) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082510-A1 Psoralens for pathogen inactivation BPGM, XPA, RAD50 MAPT 2933/4885KDM4E 3035/4885ALDH1A1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.